On January 29, 2004, Yamada, Rintaro; Seto, Minoru published a patent.Safety of 4-Bromo-5-nitroisoquinoline The title of the patent was Preparation of 5-substituted isoquinoline derivatives as myosin regulatory light-chain phosphorylation inhibitors. And the patent contained the following:
The title compounds I [wherein R1 = H, halo, OH, NH2, or alkoxy; R2 = H, halo, alkenyl, alkynyl, alkoxy,alkylthio, alkyl-SO, alkylsulfonyl, CN, (un)substituted alkyl, amino, etc.; R3 = (un)substituted OH, SO2NH2, or NH2] or salts thereof are prepared as myosin regulatory light-chain phosphorylation inhibitors. For example, N-(tert-butoxycarbonyl)-1,3-propanediamine was reacted with isoquinoline-5-sulfonyl chloride in CH2Cl2 in the presence of NEt3 to give the sulfonamide. The sulfonamide was reacted with 3-phenyl-1-propanol in THF in the presence of 1,1′-azobis(N,N-dimethylformamide) and Bu3P, followed by hydrolysis to provide II•xHCl. II showed inhibitory activity with IC50 of 0.8 μM against human myosin regulatory light-chain phosphorylation. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Safety of 4-Bromo-5-nitroisoquinoline
The Article related to isoquinoline myosin regulatory light chain phosphorylation inhibitor preparation human, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Safety of 4-Bromo-5-nitroisoquinoline
Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem